NovoCure Limited (NASDAQ:NVCR) Director Gabriel Leung sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, June 7th. The stock was sold at an average price of $204.55, for a total transaction of $204,550.00. Following the sale, the director now directly owns 73,045 shares in the company, valued at approximately $14,941,354.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Gabriel Leung also recently made the following trade(s):
- On Wednesday, May 5th, Gabriel Leung sold 1,000 shares of NovoCure stock. The stock was sold at an average price of $199.67, for a total transaction of $199,670.00.
- On Tuesday, April 13th, Gabriel Leung sold 6,000 shares of NovoCure stock. The stock was sold at an average price of $198.84, for a total transaction of $1,193,040.00.
Shares of NVCR stock opened at $217.48 on Friday. The company has a fifty day moving average price of $187.26. The company has a quick ratio of 8.94, a current ratio of 9.19 and a debt-to-equity ratio of 1.50. The stock has a market cap of $22.49 billion, a price-to-earnings ratio of 1,977.27 and a beta of 1.08. NovoCure Limited has a fifty-two week low of $55.40 and a fifty-two week high of $220.48.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Sterling Financial Planning Inc. purchased a new position in shares of NovoCure during the 4th quarter worth $26,000. RWM Asset Management LLC purchased a new position in shares of NovoCure during the 4th quarter worth $35,000. NEXT Financial Group Inc purchased a new position in shares of NovoCure during the 4th quarter worth $35,000. Captrust Financial Advisors raised its holdings in shares of NovoCure by 316.5% during the 1st quarter. Captrust Financial Advisors now owns 354 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 269 shares during the period. Finally, Regent Peak Wealth Advisors LLC purchased a new position in shares of NovoCure during the 4th quarter worth $58,000. Institutional investors and hedge funds own 71.78% of the company’s stock.
A number of research firms recently issued reports on NVCR. Truist lifted their price target on shares of NovoCure from $132.00 to $142.00 in a research note on Monday, April 19th. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Wednesday, May 12th. Northland Securities lifted their price target on shares of NovoCure from $200.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, April 14th. Wedbush reissued an “underperform” rating and issued a $154.00 price target (down previously from $159.00) on shares of NovoCure in a research note on Tuesday, April 20th. Finally, Mizuho lifted their price target on shares of NovoCure from $175.00 to $242.00 and gave the company a “buy” rating in a research note on Wednesday, April 14th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $195.71.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
Featured Article: Why do companies issue monthly dividends?
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.